2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)

Modify Date: 2024-01-10 19:56:58

2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1) structure	Common Name	2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)
	CAS Number	1451048-94-4	Molecular Weight	334.801
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₆H₁₉ClN₄O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of 2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)

Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].

Name	2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)
Synonym	More Synonyms

Description	Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Epigenetics >> Histone Methyltransferase Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
Target	D2 Receptor D3 Receptor
In Vitro	Piribedil dihydrochloride (0-160 μM, 7 days) specifically inhibits MLL1 methyltransferase activity and selectively suppresses MLL-r cell proliferation[4]. Piribedil dihydrochloride (0-160 μM, 4 days) selectively decreases the H3K4 methylation in MLL-r cells (THP-1 and MV4;11), by disturbing the MLL1-WDR5 interaction[4]. Piribedil dihydrochloride (0-160 μM, 4 days) induces cell-cycle arrest, apoptosis and differentiation in MLL-r cells (THP-1 and MV4;11)[4]. Cell Viability Assay[4] Cell Line: MLL-r AML cells (THP-1 and MV4;11), non-MLL leukemia cell line (K562) Concentration: 0, 20, 40, 80 and 160 μM Incubation Time: 0-7 days Result: Inhibited the growth rate of the THP-1 and MV4;11 cells in a time-dependent manner. Western Blot Analysis[4] Cell Line: THP-1 and MV4;11 cells Concentration: 0, 20, 40, 80 and 160 μM Incubation Time: 4 days Result: Decreased the levels of H3K4me2 and H3K4me3 without affecting the methylation of other histones, such as H3K79, H3K36 and H3K27.
In Vivo	Piribedil dihydrochloride (intraperitoneal injection, 5, 15, 40 mg/kg ) alleviates the L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease[2]. Piribedil dihydrochloride (oral gavage, 4-5 mg/kg, daily for 2 weeks) increases locomotor activity and reversal of motor deficits in adult common marmosets[3]. Piribedil dihydrochloride (oral gavage, 150 mg/kg, daily for 21 days) inhibits MLL-r tumor growth and decreases the expression of MLL1 target genes in MV4;11 tumor xenografts[4]. Animal Model: Rat model of Parkinson’s disease[2] Dosage: 5, 15, 40 mg/kg Administration: Intraperitoneal injection, administered 5 min before administration of L-DOPA. Result: Reduced turning behaviour and AD (axial dystonia), OD (orolingual dyskinesia) and FD (forelimb dyskinesia) at 5 and 40 mg/kg. Increased LD (locomotive dyskinesias) at the 40 mg/kg. Animal Model: Adult common marmosets[3] Dosage: 4-5 mg/kg Administration: Oral gavage, daily for 2 weeks Result: Increased vigilance and alertness and reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum.
References	[1]. Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16(6):1077-82. [2]. Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. J Neural Transm (Vienna). 2013 Jan;120(1):31-6. [3]. Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901. [4]. Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.

Molecular Formula	C₁₆H₁₉ClN₄O₂
Molecular Weight	334.801
Exact Mass	334.119659

2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)

2-[4-(1,3-Benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine hydrochloride (1:1)

Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-, hydrochloride (1:1)

MFCD09971034

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3

2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)

Use of 2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine hydrochloride (1:1)

Names

Biological Activity

Chemical & Physical Properties

Synonyms